



S

Research Grade Cilgavimab

Catalog No.	DVV00302A DVV00302B	Quantity:	100 µg 1.0 mg
Alternate Names:	Cilgavimab, COV2-2130, AZD1061		
Description:	<p>Cilgavimab (AZD1061) was derived from B-cells donated by convalescent patients after SARS-CoV-2 viral infection. AZD1061 is able to block the binding of the SARS-CoV-2 virus to host cells and protect against infection in cell and animal models of disease. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Spike glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.</p>		
UniProt ID (target):	P0DTC2		
Origin:	Derived from B-cells donated by convalescent patients after infection with SARS-CoV-2 virus		
Specificity:	Recognizes SARS-CoV-2 Spike-RBD protein, EC ₅₀ = 0.06395 with Omicron RBD		
Source:	XtenCHO		
Purity:	> 95% by reduced and non-reduced SDS-PAGE		
Isotype:	Human IgG1 kappa		
Clone:	AZD1061 or COV2-2130		
Concentration:	1.0 mg/ml, lot specific		
Formulation:	Sterile-filtered 0.01M PBS, pH 7.4		
Purification:	Protein A affinity chromatography		
Endotoxin:	< 0.01 EU/µg by LAL analysis		
Applications:	Neutralization, Functional Studies		
Storage & Stability:	<p>Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare single-use aliquots of undiluted product and store -20°C to -80°C. Avoid repeated freeze/thaw cycles.</p>		



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

